Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Shiitake mushrooms (Lentinula edodes) have been investigated for their potential immunomodulatory properties, primarily due to bioactive compounds such as lentinan, a beta-glucan. Several clinical and preclinical studies have explored lentinan as an adjunctive therapy in individuals with compromised immune systems, including those with Acquired Immune Deficiency Syndrome (AIDS). Early studies from the 1980s and 1990s reported that lentinan could enhance certain immune parameters in HIV-positive individuals, such as increasing CD4+ cell counts and improving immune response. However, these studies often had small sample sizes and methodological limitations.

Lentinan has been studied more extensively in cancer and as an adjunct in chemotherapy for its immune-boosting effects. For HIV/AIDS, the evidence is less robust. A handful of clinical trials and case reports suggest potential benefits, but systematic reviews and larger randomized controlled trials are lacking. While shiitake extracts are not part of standard HIV/AIDS treatment protocols, their use as a complementary therapy has some scientific rationale based on their immunomodulatory effects. The overall quality and quantity of evidence supporting shiitake or lentinan specifically for AIDS management remain limited, and mainstream guidelines do not recommend its use for this purpose. Thus, the evidence rating is moderate to low, with some scientific basis but insufficient high-quality clinical validation.

More about Shiitake
More about Acquired Immune Deficiency Syndrome

Other ingredients used for Acquired Immune Deficiency Syndrome

Other health conditions supported by Shiitake

Products containing Shiitake